# Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin

> **NCT01012336** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 89 (actual)

## Conditions studied

- Chemotherapy-Induced Nausea and Vomiting
- Ovarian Cancer

## Interventions

- **DRUG:** Aprepitant/Ramosetron/Dexamethasone

## Key facts

- **NCT ID:** NCT01012336
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-10
- **Final completion:** 2012-04
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2012-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01012336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01012336, "Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01012336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*